ACE2 and viral infectious disease: Recently there have also been reports of miniprotein inhibitors of the SARS‐CoV‐2/ACE2 PPI with picomolar RBD binding affinity and comparable activity with ACE2 in cell‐based assays.[29] These data, together with that presented here, indicate that larger ligands with enhanced binding interactions are required for effective SARS‐CoV‐2 S‐protein RBD binding, to outcompete membrane bound ACE2 and effectively prevent viral infection.